A Cross-Sectional Study on Post-Coronavirus Disease (COVID-19) Hair Loss at a Tertiary Care Hospital
Keywords:
COVID-19, telogen effluvium, trichoscopy, patterned hair loss, hair lossAbstract
Background: Severe acute respiratory virus syndrome coronavirus 2 (SARS-CoV-2) was responsible for coronavirus disease (COVID-19) pandemic. As patients recovered from COVID-19 infection, hair loss was increasingly observed as a distressing symptom.
Methods: This was a prospective cross-sectional study of patients with post COVID-19 hair loss between July to December 2021 at a tertiary care centre. Detailed history, clinical examination, trichoscopy and biochemical tests were performed and recorded. COVID-19 disease severity was assessed based on duration of COVID-19 infection and place of management.
Results: The study included 120 patients with mean age being 39.6 years. Majority of the patients were females, treated at home and had COVID-19 infection for >2 weeks. Mean visual analog scale (VAS) score for stress was 5.25. Vitamin D deficiency was present in 56.7% and low ferritin in 30% of cases. Mean time of onset of hair loss post COVID-19 was 49 days. Patients mainly presented with diffuse hair loss. Trichodynia was present in 15.8% of cases. The degree of hair loss was severe in 55.8% of the subjects. Positive hair pull test was seen in 65% of patients. Most common trichoscopic features included single hair follicles’ (81.7%) and vellus hair >10% (60%).
Conclusions: The mean time of onset of hair loss post COVID-19 infection was less than 2 months. Majority patients had diffuse pattern and severe degree of hair loss. Trichoscopy can aid in unmasking co-existing patterned hair loss in patients presenting clinically with diffuse hair loss.
References
Tammaro A, Adebanjo GAR, Parisella FR, Luzi F, Scarabello A. Hair and nail manifestations of COVID-19. J Cosmet Dermatol. 2022; 21: 1339– 1346. https://doi.org/10.1111/jocd.14774
Abdulwahab RA, Aldajani BM, Natto NK, et al. Prevalence of Hair Loss After COVID-19 Infection in Makkah Region, Saudi Arabia. Cureus. 2022;14(9):e29285:1-8. https://doi.org/10.7759/cureus.29285
Wei KC, Yang CC. Hair loss and COVID-19. Dermatol Sin. 2021;39:167-8. https://doi.org/10.4103/ds.ds_52_21
Wambier C.G, Vaño-Galván S, McCoy J, et al. Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The “Gabrin sign”. J Am Acad Dermatol. 2020;83:680–682. https://doi.org/10.1016/j.jaad.2020.05.079
Gentile P. Hair loss and telogen effluvium related to COVID-19: The potential implication of adipose-derived stem cells and platelet-rich plasma as regenerative strategies. Int J Mol Sci. 2022;23:9116. https://doi.org/10.3390/ijms23169116
Torabi S, Mozdourian M, Rezazadeh R, Payandeh A, Badiee S, Darchini-Maragheh E. Androgenetic alopecia in women and men is not related to COVID-19 infection severity: A prospective cohort study of hospitalized COVID-19 patients. J Eur Acad Dermatol Venereol. 2021;35:e553-6. https://doi.org/10.1111/jdv.17353
Tanha HM, Medland S, Martin NG, Nyholt DR. Genetic correlation analysis does not associate male pattern baldness with COVID-19. J Am Acad Dermatol. 2021;85:971-3. https://doi.org/10.1016/j.jaad.2021.05.009.
Czech T, Sugihara S, Nishimura Y. Characteristics of hair loss after COVID-19: A systematic scoping review. J Cosmet Dermatol. 2022;21:3655-3662. https://doi.org/10.1111/jocd.15218.
Lopez‐Leon S, Wegman‐Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long‐term effects of COVID‐19: a systematic review and metaanalysis. Sci Rep. 2021;11(1):16144. https://doi.org/10.1101/2021.01.27.21250617
Rossi A, Magri F, Sernicola A, et al. Telogen Effluvium after SARS-CoV-2 Infection: A Series of Cases and Possible Pathogenetic Mechanisms. Skin Appendage Disord. 2021;21:1-5. https://doi.org/10.1159/000517223
Sharquie KE, Jabbar RI. COVID-19 infection is a major cause of acute telogen effluvium. Irish J Med Sci. 2022 ;191(4):1677-1681. https://doi.org/10.1007/s11845-021-02754-5
Babaei K, Kavoussi H, Rezaei M, Kavoussi R. Characteristics of telogen effluvium in COVID-19 in western Iran (2020). An Bras Dermatol. 2021; 96(6):688-692. https://doi.org/ 10.1016/j.abd.2021.05.006
Roda Â, Oliveira-Soares R. Acute telogen effluvium in patients recently infected with SARS-CoV-2. J Port Soc Dermatol Venereol. 2021; 79(1),21-25. https://doi.org/10.29021/spdv.79.1.1299
Moreno-Arrones OM, Lobato-Berezo A, Gomez-Zubiaur A, Arias-Santiago S, Saceda-Corralo D, Bernardez-Guerra C, et al. SARS-CoV-2-induced telogen effluvium: a multicentric study. J Eur Acad Dermatol Venereol. 2020; 35: e181-e183. https://doi.org/10.1111/jdv.17045
Seyfi S, Alijanpour R, Aryanian Z, Ezoji K, Mahmoudi M. Prevalence of telogen effluvium hair loss in COVID-19 patients and its relationship with disease severity. J Med Life. 2022;15(5):631. https://doi.org/10.25122/jml-2021-0380
Rivetti N, Barruscotti S. Management of telogen effluvium during the COVID-19 emergency: Psychological implications. Dermatol Ther. 2020;33(4):e13648. https://doi.org/10.1111/dth.13648
Gadzhigoroeva A, Sanchez DG, Firooz A, et al. COVID-19 Can Exacerbate Pattern Hair Loss and Trigger Telogen Effluvium - The Role of Proteoglycan Replacement Therapy with Nourkrin® in Clinical Treatment of COVID-19 Associated Hair Loss. J Dermatol Res Ther. 2021;7:103. https://doi.org/10.23937/2469-5750/151010
Hussain N, Agarwala P, Iqbal K, et al. A systematic review of acute telogen effluvium, a harrowing post‐COVID‐19 manifestation. J Med Virol. 2022;94:1391‐1401. https://doi.org/10.1002/jmv.27534
Rizzetto G, Diotallevi F, Campanati A, et al. Telogen effluvium related to post severe Sars-Cov-2 infection: Clinical aspects and our management experience. Dermatol Ther. 2020;e14547. https://doi.org/10.1111/dth.14547
Monari P, Gualdi G, Bettoni G, et al. Post-SARS-CoV-2 Acute Telogen Effluvium: An Expected Complication. J Clin Med. 2022;11:1234:1-8. https://doi.org/10.3390/jcm11051234
Abrantes TF, Artounian KA, Falsey R, et al. Time of onset and duration of post-COVID-19 acute telogen effluvium. J Am Acad Dermatols. 2021;1;85(4):975-6. https://doi.org/10.1016/j.jaad.2021.07.021
Starace M, Iorizzo M, Sechi A, et al. Trichodynia and telogen effluvium in COVID-19 patients: Results of an international expert opinion survey on diagnosis and management. J Am Acad Dermatol Int. 2021;1;5:11-8. https://doi.org/ 10.1016/j.jdin.2021.07.006
Ocampo-Garza J, Tosti A. Trichoscopy of dark scalp. Skin appendage disord. 2019;5(1):1-8. https://doi.org/10.1159/000488885
Mieczkowska K, Deutsch A, Borok J, et al. Telogen effluvium: a sequela of COVID‐19. Int J Dermatol. 2021;60(1):122-124. https://doi.org/10.1111/ijd.15313
Govindarajulu SM, Srinivas RT, Kuppuswamy SK, Prem P. Trichoscopic patterns of nonscarring alopecia's. Int J Trichology. 2020;12(3):99. https://doi.org/10.4103/ijt.ijt_1_19
Domínguez-Santás M, Haya-Martínez L, Fernández-Nieto D, Jiménez-Cauhé J, Suárez-Valle A, Díaz-Guimaraens B. Acute telogen effluvium associated with SARS-CoV-2 infection. Aust J Gen Pract. 2020;49:10.31128/AJGP-COVID-32. https://doi.org/10.31128/AJGP-COVID-32
Di Landro A, Naldi L, Glaser E, Paus R, Tosti A. Pathobiology questions raised by telogen effluvium and trichodynia in COVID-19 patients. Exp Dermatol. 2021;30(7):999-1000. https://doi.org/10.1111/exd.14352
Lv S, Wang L, Zou X, Wang Z, Qu B, Lin W, Yang D. A Case of Acute Telogen Effluvium After SARS-CoV-2 Infection. Clin Cosmet Investig Dermatol. 2021;16;14:385-387. https://doi.org/10.2147/CCID.S307982.
Aryanian Z, Balighi K, Hatami P, Afshar ZM, Mohandesi NA. The role of SARS‐CoV‐2 infection and its vaccines in various types of hair loss. Dermatol Ther. 2022;35(6):e15433. https://doi.org/10.1111/dth.15433
Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat med. 2021;27(4):601-15. https://doi.org/10.1038/s41591-021-01283-z
Published
Issue
Section
License
Copyright (c) 2023 Dhaarna Wadhwa, Avneet Monga, Neha Kumar, Geeti Khullar, Sanchita Karmakar, Niti Khunger
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
Share
